Trial Profile
A Phase II Clinical Trial of Radium-223 Activity in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms EXCAAPE
- 15 Aug 2022 Results published in the European Journal of Cancer
- 23 Nov 2020 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Primary endpoint (Assess the efficacy of radium-223 in terms of radiological rPFS) has been met, as per results presented at the 45th European Society for Medical Oncology Congress